If this message does not display properly, please click here to launch your browser
| Is Cerezyme’s Heyday Over? Shire and Pfizer/Protalix Are Poised to Challenge Genzyme’s Dominance in Gaucher’s Disease – But Will They Succeed? — A Pharmaview Competitive Assessment from Decision Resources | |||
Decision Resources is offering an exclusive Pharmaview competitive assessment entitled Is Cerezyme’s Heyday Over? Shire and Pfizer/Protalix Are Poised to Challenge Genzyme’s Dominance in Gaucher’s Disease – But Will They Succeed? This session is ONLY available to Pharmaview subscribers. Please contact us to learn how you can become a Pharmaview subscriber and attend this event. Last year, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency granted Gaucher’s disease patients access, on a pre-approval basis, to two novel Phase III enzyme replacement therapies—Shire’s VPRIV (velaglucerase alfa) and Pfizer/Protalix’s Uplyso (taliglucerase alfa). This action was taken after a viral contamination at a Genzyme manufacturing facility resulted in global shortages of Genzyme’s Gaucher’s disease treatment, Cerezyme. Given their accelerated progression to market, both VPRIV and Uplyso were the subject of much discussion at last month’s Lysosomal Disease Network WORLD Symposium 2010. In order to assess the impact of the data presented at this year’s conference, Decision Resources interviewed U.S. and European thought leaders to discuss whether the emerging therapies, including Genzyme’s promising Phase III oral substrate reduction therapy, eliglustat tartrate, will gain traction and succeed in the Gaucher’s disease drug market. This session, presented by Pharmaview analyst Ben Duncan, will answer the following questions as they relate to data presented at the Lysosomal Disease Network conference:
Mr. Duncan will conduct a live Q & A session after the presentation. Registration Is Cerezyme’s Heyday Over? Shire, Pfizer/ Protalix Are Poised to Challenge Genzyme’s Dominance in Gaucher’s Disease – But Will They Succeed? March 4, 2010 at 10 a.m. U.S. Eastern Time, 4 p.m. Central European Time (Paris). To learn how you can become a Pharmaview subscriber and attend this event, please contact us using the information below. In North America — Jaclyn Jordan at 781-296-2662 or jjordan@dresources.com |
|
||
Terms of Use | Privacy Policy | Contact Us | Careers |
|||
Ben Duncan is a metabolic analyst on the Decision Resources’ Pharmaview team. Since joining Decision Resources in 2007 from Synergy Healthcare Research, Mr. Duncan has authored several indication specific market research reports on diabetic nephropathy, obesity, and post-myocardial infarction. Mr. Duncan holds a B.Sc. in psychology from the University of Warwick. 